With a street-high upside potential of 109.4%, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the 10 best robotics ...

Good afternoon, and thank you for joining us. While our commercial realignment initiatives modestly affected Q1 procedure growth, performance was largely in line with expectations. Regarding ...

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.45 per share a year ago.

PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of ...

This surgical robotics firm develops minimally invasive systems for urologic procedures, targeting hospitals and specialty ...

Investors in PROCEPT BioRobotics Corp (Symbol: PRCT) saw new options begin trading this week, for the July 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

PROCEPT BioRobotics Corp. Annual stock financials by MarketWatch. View the latest PRCT financial statements, income statements and financial ratios.

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on PRCT. PROCEPT ...

NEW YORK, March 18, 2026 /PRNewswire/ -- Procept BioRobotics (NASDAQ: PRCT) guided investors toward $325.5 million in full-year 2025 revenue -- representing 45% growth -- then delivered $308.1 million ...

PROCEPT BioRobotics Corp. Annual stock financials by MarketWatch. View the latest PRCT financial statements, income statements and financial ratios.